Oxford Biomedica OXBDF Stock
Oxford Biomedica Price Chart
Oxford Biomedica OXBDF Financial and Trading Overview
| Oxford Biomedica stock price | 3.95 USD |
| Previous Close | 5.79 USD |
| Open | 5.79 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 5.79 - 5.79 USD |
| 52 Week Range | 3.35 - 6.7 USD |
| Volume | 50 USD |
| Avg. Volume | 4.24K USD |
| Market Cap | 562.28M USD |
| Beta (5Y Monthly) | 0.922222 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -55.38 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
OXBDF Valuation Measures
| Enterprise Value | 561.88M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.0165987 |
| Price/Book (mrq) | 2.7234244 |
| Enterprise Value/Revenue | 4.014 |
| Enterprise Value/EBITDA | -22.447 |
Trading Information
Oxford Biomedica Stock Price History
| Beta (5Y Monthly) | 0.922222 |
| 52-Week Change | 10.91% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.7 USD |
| 52 Week Low | 3.35 USD |
| 50-Day Moving Average | 5.52 USD |
| 200-Day Moving Average | 5.07 USD |
OXBDF Share Statistics
| Avg. Volume (3 month) | 4.24K USD |
| Avg. Daily Volume (10-Days) | 5.01K USD |
| Shares Outstanding | 96.52M |
| Float | 69.74M |
| Short Ratio | N/A |
| % Held by Insiders | 8.56% |
| % Held by Institutions | 61.13% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -27.97% |
| Operating Margin (ttm) | -33.18% |
| Gross Margin | 49.41% |
| EBITDA Margin | -17.88% |
Management Effectiveness
| Return on Assets (ttm) | -8.32% |
| Return on Equity (ttm) | -21.32% |
Income Statement
| Revenue (ttm) | 139.99M USD |
| Revenue Per Share (ttm) | 1.48 USD |
| Quarterly Revenue Growth (yoy) | 23.40% |
| Gross Profit (ttm) | N/A |
| EBITDA | -25031000 USD |
| Net Income Avi to Common (ttm) | -39157000 USD |
| Diluted EPS (ttm) | -0.52 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 141.31M USD |
| Total Cash Per Share (mrq) | 1.47 USD |
| Total Debt (mrq) | 114.28M USD |
| Total Debt/Equity (mrq) | 48.39 USD |
| Current Ratio (mrq) | 3.612 |
| Book Value Per Share (mrq) | 2.126 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -12615000 USD |
| Levered Free Cash Flow (ttm) | -12800250 USD |
Profile of Oxford Biomedica
| Country | United States |
| State | N/A |
| City | Oxford |
| Address | Windrush Court |
| ZIP | OX4 6LT |
| Phone | 44 1865 783 000 |
| Website | https://www.oxb.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 894 |
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological malignancies and tumours; and OXB-401 that is in pre-clinical stage for the treatment of liver indication; as well as OXB-40X, OXB-40Y, and OXB-40Z, which are in pre-clinical stage for liver indication. The company has collaborations with Boehringer Ingelheim, Immatics, Arcellx, Orchard, and Beam Therapeutics; an agreement with Homology Medicines; license and clinical supply agreement with Juno Therapeutics, Inc.; and master services and development agreement with AstraZeneca UK Ltd and Serum Life Sciences Ltd. The company also has a strategic collaboration with Kite Pharma to develop and commercialize CART-ddBCMA, a lead late-stage product candidate. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Q&A For Oxford Biomedica Stock
What is a current OXBDF stock price?
Oxford Biomedica OXBDF stock price today per share is 3.95 USD.
How to purchase Oxford Biomedica stock?
You can buy OXBDF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Oxford Biomedica?
The stock symbol or ticker of Oxford Biomedica is OXBDF.
Which industry does the Oxford Biomedica company belong to?
The Oxford Biomedica industry is Biotechnology.
How many shares does Oxford Biomedica have in circulation?
The max supply of Oxford Biomedica shares is 106.6M.
What is Oxford Biomedica Price to Earnings Ratio (PE Ratio)?
Oxford Biomedica PE Ratio is now.
What was Oxford Biomedica earnings per share over the trailing 12 months (TTM)?
Oxford Biomedica EPS is -55.38 USD over the trailing 12 months.
Which sector does the Oxford Biomedica company belong to?
The Oxford Biomedica sector is Healthcare.